Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.60 |
| ▸ | RAB9A | P51151 | 9/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | GRM5 | P41594 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28567406 | 0.81 | NPC1 (0.53) | NPC1RAB9APKMSMN1; SMN2CYP1A2 | |
| SCHEMBL4782545 | 0.76 | L3MBTL1 (0.59) | NPC1RAB9ASMN1; SMN2CYP1A2KMT2A | |
| SCHEMBL9384187 | 0.75 | NPC1 (0.72) | NPC1RAB9APKMSMN1; SMN2CYP1A2 | |
| SCHEMBL28720941 | 0.75 | RAB9A (0.77) | NPC1RAB9APKMSMN1; SMN2CYP1A2 | |
| SCHEMBL5558079 | 0.75 | NPC1 (0.60) | NPC1RAB9APKMSMN1; SMN2CYP1A2 | |
| SCHEMBL4725839 | 0.75 | CCNA2 (0.63) | NPC1RAB9ASMN1; SMN2CYP1A2KDM4E | |
| SCHEMBL29366822 | 0.74 | RAB9A (0.89) | NPC1RAB9APKMSMN1; SMN2CYP1A2 | |
| SCHEMBL997866 | 0.74 | RAB9A (0.89) | NPC1RAB9APKMSMN1; SMN2CYP1A2 | |
| SCHEMBL483177 | 0.74 | RAB9A (0.49) | RAB9ASMN1; SMN2KMT2AMEN1KDM4E | |
| SCHEMBL3759858 | 0.74 | NR3C1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286779-A1 | PYRAZOLOPYRIMIDINES AS LIPID KINASE INHIBITORS | NOVARTIS AG | 2009-11-19 | — | — | US | claimed |
| EP-2081933-A1 | PYRAZOLOPYRIMIDINES AS P13K LIPID KINASE INHIBITORS | Novartis Ag (CH) | 2009-07-29 | — | — | EP | claimed |
| WO-2008037477-A1 | PYRAZOLOPYRIMIDINES AS P13K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | claimed |
| WO-2022143856-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-07-07 | — | — | WO | disclosed |
| WO-2020228637-A1 | SUBSTITUTED 1-AMINO-1H-IMIDAZOLE-5-CARBOXAMIDE AS BRUTON'S TYROSINE KINASE INHIBITORS | HENAN NORMAL UNIVERSITY (CN) | 2020-11-19 | — | — | WO | disclosed |
| WO-2016192074-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-20090286779-A1 | PYRAZOLOPYRIMIDINES AS LIPID KINASE INHIBITORS | NOVARTIS AG | 2009-11-19 | — | — | US | disclosed |
| EP-2081933-A1 | PYRAZOLOPYRIMIDINES AS P13K LIPID KINASE INHIBITORS | Novartis Ag (CH) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008037477-A1 | PYRAZOLOPYRIMIDINES AS P13K LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286779-A1 | PYRAZOLOPYRIMIDINES AS LIPID KINASE INHIBITORS | ATR, ATM, CHEK1 | NPC1 1299/4885RAB9A 2181/4885PKM 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.